The INTRICATE program has brought forward a strategic platform biomedical nanotechnology to develop assets in the field of rheumatology, orthopedics and tissue engineering. It is a novel compound featuring as a modular acellular 3D scaffold.
Building on our platform technology, we can develop acellular scaffolds. These stimulate cell proliferation and can be loaded with small molecules or growth factors. We have reached above satisfactory results in regenerating various tissue types in preclinical models, both with and without growth factors.
The development strategy for INTRICATE is to advance multiple INTRICATE candidates across different selectivity profiles, and to test these in a broad panel of in vivo rheumatic and degenerative disease as well as traumatic models targeting a number of indications, with a key focus on tissue regeneration.